馬德里加爾製藥公司（納斯達克股票代碼：MDGL）報告季度每股虧損$(2.71)，優於分析師預期的$(4.16)，增幅爲34.86%。與去年同期每股虧損$(5.68)相比，這是一個52.29%的提升。公司報告季度銷售額爲1.0322億美元，優於分析師預期的9856萬美元，增幅爲4.73%。

以上內容來自Benzinga Earnings專欄，原文如下：

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(2.71) per share which beat the analyst consensus estimate of $(4.16) by 34.86 percent. This is a 52.29 percent increase over losses of $(5.68) per share from the same period last year. The company reported quarterly sales of $103.22 million which beat the analyst consensus estimate of $98.56 million by 4.73 percent.